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1. Introduction 
In the last 10 years, microRNAs (miRNAs) have emerged as critical regulators of 
numerous physiological and pathological mechanisms [1-2], including cardiac and 
vascular smooth muscle cell (VSMC) plasticity [3-5]. These small molecules (approx. 20 to 
25 nucleotides) comprise a novel and abundant class of endogenous interfering RNAs. 
More than 1 500 miRNAs are now listed by dedicated internet databases such as miRBase, 
Tarbase, MicroRNA.org or miRdb (See sub-chapter II for URL adresses). They are 
transcribed and matured, in a process known as miRNA biogenesis [6] which starts with 
the transcription of a larger RNA product, called pri-miRNA, by the RNA polymerase II 
in the vast majority of cases. Pri-miRNA, which is a few hundred to a few thousand 
nucleotides long, is then submitted to cleavage in the nucleus by a specific RNase III 
(Drosha) and its protein partner, DiGeorge syndrome critical region 8 (DGCR8), near the 
base of the miRNA hairpin stem. This process releases a pre-miRNA hairpin (of approx. 
60 to 70 nt). The pre-miRNA is then released in the cytoplasm where it is recognized and 
cleaved within its stems by the Dicer RNase III and its protein partners. This results in a 
double stranded RNA, known as the miRNA/miRNA* duplex (approx. 22 bp). This 
complex is unwound to single strands. One strand (guiding strand / mature miRNA) is 
incorporated in the RNA-induced-silencing complex (RISC) that contains Argonaute 2 
(Ago2), another endonuclease, the other strand is usually rapidly degraded. Finally, the 
RISC complex carries the mature miRNA to its target messenger RNAs (mRNAs), which 
results in gene silencing, in a post-transcriptional manner [7]. Figure 1 shows a 
representative example of the biogenesis of miR-143 and miR-145, which are the main 
miRNAs expressed in smooth muscle cells. 
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Figure 1. Schematic representation of the miR-143/145 cluster biogenesis, which expresses the main 
miRNAs in vascular smooth muscle. The transcription factor Myocardin in complex with its cofactor 
Serum Response Factor (SRF) binds CArG box-containing promoters, which then activates the tran-
scription of the miR-143/145 cluster. MiR-143 and 145 are cotranscribed as a single pri-miRNA tran-
script. The Drosha and DGCR8 (DiGeorge Syndrome Critical Region 8) complex processes the pri-
miRNA into a hairpin-structured pre-miRNA. The pre-miRNAs corresponding to miR-143 and 145 are 
exported by a nucleocytoplasmic shuttle protein known as exportin, from the nucleus to the cytoplasm 
and are then cleaved by the Dicer complex into miRNA duplexes. The miRNA duplexes are finally 
unwound to obtain the mature miR-143 and miR-145, which are incorporated into the RNA-induced 
silencing complex (RISC) and bind various mRNA targets in their 3’ untranslated region. In vascular 
smooth muscle cells (VSMCs), miR-143 and 145 inhibit the expression of CaMKII (Ca2+/calmodulin-
dependent protein kinases II) and Elk-1 (E twenty-six (ETS)-like transcription factor 1), which induces a 
repression of VSMC survival and proliferation. Also, the miR-143 and 145 inhibit the expression of 
Fascin, PDGF-Rα (Platelet-derived growth factor receptor α) and PKCε (Protein Kinase Cε) which 
induces a repression of VSMC migration and of the vascular remodeling. Finally, miR-143 and 145 also 
inhibit the expression of KLF4 and 5 which are repressors of Myocardin activity. As a consequence, 
VSMC differentiation is maintained.Adapted from [3]. 
Determining how the RISC complex carries a specific miRNA to its target mRNAs, and thus 
regulates gene expression, remains an intense field of research. The most important feature 
in the miRNA sequence is a short but critical region called the seed sequence, which is only 
7 nts long, and most of the times, located in nucleotides in positions 2 to 8 of the miRNA. 
The base-pairing uses canonical Watson-Crick complementarity. Conversely, this small 
stretch of nucleic acids is a useful tool to classify miRNA into families based on shared seed 
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sequences. Since the miRNA seed is so short, each miRNA can potentially bind hundreds of 
target mRNAs when one considers the large number of possible binding sites in mRNA 
regulatory sequences. This is one of the reasons why one single miRNA can regulate the 
expression of multiple target genes, by binding as many as several hundreds of mRNA 
targets. This clearly shows the role of these small RNAs in the intricate tapestry of gene 
regulations. Another, foremost reason for this complexity is that miRNAs, outside of the 
seed region, bind their mRNA targets mostly as imperfect complements. Similarly, one 
mRNA can be regulated by several miRNAs. All this further explains how the 1 500 
miRNAs known to date are able to regulate the expression of approximately one third of the 
human genes. Thus, microRNAs are likely to impact multiple mechanisms of gene 
regulation and developmental pathways, by using extensive regulatory gene expression 
networks [1-2]. 
The current paradigm states that miRNAs act mostly by inhibiting the translation of their 
target mRNAs, rather than by inducing their degradation. Bartel’s team has however recent-
ly challenged that view by showing that, in a vast majority of cases, mammalian microRNAs 
act by destabilizing their target mRNAs and by decreasing their levels [8]. No matter the 
case, a wide consensus agrees that miRNAs are posttranscriptional regulators which bind to 
their target mRNAs, mostly in their 3’ Untranslated Region (UTR). Note, however, that 
recent unbiased studies have shown that, in some particular cases, miRNAs bind the coding 
region or 5’UTR of respective target mRNAs ([9-11]. 
The miRNA nomenclature is remarkably standardized and straightforward [12]: the pre-
fix "mir" is followed by a dash and an assigned number, reflecting the prevalence of dis-
covery, to experimentally confirmed miRNAs. Gene is referred to in italic, eg mir-143. The 
pre-miRNA is designated by the suffix mir-, eg mir-143. Finally, the mature miRNA is 
abbreviated miR-, eg miR-143. MiRNAs with similar sequences / structure except for 1-2 
nts, will be assigned a supplementary letter, eg miR-29a, miR-29b, miR-29c and often 
originate from the same gene. Different loci will produce different pre-miRNAs, but yield 
a mature miRNA with the precise same sequence. In this case, the nomenclature miR-1-1, 
miR-1-2 etc will be used. In some cases, one pre-miRNA will result in two different ma-
ture miRNAs, one from the 5-prime stem and one originating from the 3-prime stem. 
They will be designated by the suffixes miR-142-5p and miR-142-3p. Species can also be 
taken into consideration: hsa-miR refers to Homo sapiens miRNAs, mmu-miRNAs to Mus 
musculus, etc. 
Mature miRNA sequences and pathways are remarkably preserved throughout phylogeny. 
Also, the evolutionary complexity of multicellular organisms positively correlates with the 
number of miRNA genes, their expression, and the diversity of their targets [13]. This re-
markable conservation is used by most miRNA target prediction algorithms. These dedicat-
ed softwares use a standardized method to evaluate interactions between miRNAs and their 
specific target mRNAs based on (1) complementarity between mRNA 3’ UTR and miRNA 
seed sequence and (2) the degree of conservation of miRNA across species (see subchapter 2 
for url adresses). The end result is straightforward: the higher the conservation, the higher 
the score given. 
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2. Current methods for studying miRNAs: Functional analysis 
Various techniques have been developed over the last decade to quantify the expression of 
miRNAs and study their function (extensively reviewed in [14]). Figure 2 exposes the most 
widely used methods. Northern blotting was first used to quantify miRNAs, but this tedious 
technique, relying on radioactive labeling, was rapidly replaced by the much more conven-
ient qRT-PCR. Two interchanging chemistries can be used for qPCR: (1) Sybr Green, which 
is often associated with a modified oligo(dT) technique, and the adjunction of an universal 
primer for reverse transcription which enables reverse transcription of all transcripts within 
an RNA sample; therefore, target miRNA and normalizing mRNA can be analyzed from the 
same RT reaction; or (2) Taqman chemistry, in association with the use of stem-loop miR-
NA-specific RT primers to produce cDNA, with the advantage of additional specificity. Both 
give accurate results. Each method has its own assets and setbacks. Technically speaking, 
the modified oligo(dT) method requires only a single RT reaction to reverse transcribe both 
miRNA and its target mRNAs and is less time consuming. Both techniques have been opti-
mized and developed to screen most of known miRNAs in one experiment. Indeed, analysis 
of high-throughput miRNA expression remains a challenge since the number of miRNAs 
continues to increase with in silico prediction and experimental verification. Oligonucleotide 
microchip (microarray) was first widely used for high throughput miRNA screening, but a 
novel miRNA expression profiling approach, quantitative RT-PCR array (qPCR-array) is 
now rapidly gaining ground. Comparison between microarray and qPCR-array indicated a 
superior sensitivity and specificity of qPCR-array [15], and qPCR arrays are now rapidly 
becoming the method of choice. 
Over-expressing or inhibiting miRNA activity, using RNA constructs, and examining the 
resulting phenotypic effects is crucial for understanding microRNA involvement, both in 
vitro and in vivo. For that, solutions are readily available for in vitro use [16]. Knock-in is 
most of the time induced by the addition of pre-miR precursors of a particular miRNA, 
often nicknamed ”mimics”. Alternatively, viral vectors have been developed by various 
industrials, most of them relying on modified lentivirus or adeno-associated virus (AAV). 
On the other hand, knock-down is classically induced by transfection of so-called “antago-
miRs”, which have been developed to interfere with expression of a specific miRNA. These 
synthetic RNA inhibitors incorporate the reverse complement of the mature miRNA (which 
represents here the target site). They are chemically modified to enhance binding affinity 
and decrease nucleolytic cleavage by the RISC complex and degradation by other RNAses. 
The last years have also seen the development of miRNAs sponges, which are equivalent to 
the endogenous sponges described below (see sub-chapter V). These long transcripts contain 
repeated regions complementary to specific miRNAs which will bind them instead of their 
dedicated mRNA targets, thus resulting in miRNA silencing. All these techniques can also 
be implemented in vivo, in various animal models. 
Finally, classic knock-out genetic strategies can be applied to miRNA genes [17]. MiRNA-
processing proteins such as Dicer, Dgcr8, Drosha or Ago2 are essential for viability in mice. 
Knock-out mice individually lacking these key miRNA-processing genes die during early 
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gestation with severe developmental defects, including in vessels and heart. However, 
conditional murine knockout of these genes have been developed recently and offer 
valuable tools to study miRNA importance, including in the cardiac organ. Also, one can 
obtain animals models totally devoid of the miRNA of interest. We describe below the 
interesting example of mice knock-outed of the most widely expressed vascular miRNAs, 
miR-143 and miR-145 (see subchapter III, [18-20]). 
 
A- Schematic outline of microRNA RT-qPCR Systemq. (1) A poly-A tail is added to the mature microRNA template. cDNA 
is synthesized using a poly-T primer with a 3’ degenerate anchor and a 5’ universal tag. The cDNA template is then 
amplified using microRNA-specific and LNA™-enhanced forward and reverse primers. SYBR® Green is used for 
detection . (2) Taqman chemistry with the use of specific stem loop RT primers, and of an internal Taqman probe for 
qPCR quantitation. 
B-qRT-PCR arrays: The microRNA PCR array protocol is a two-part protocol consisting of, 1- First-strand cDNA synthesis, 
2- Real-time PCR amplification . Two 384-well plates enable to quantitate more than 700 miRNA in one experiment. 
C-High throughpout sequencing. Nucleotides flow sequentially over Ion semiconductor chip– Direct detection of natural 
DNA extension– A few seconds per incorporation 
D- miRNA sponges interfere with miRNA function. Sponges are ectopically expressed or artificial RNAs that contain 
multiple miRNA target sites. These target sites compete miRNAs away from their natural mRNA targets. miRNA 
sponges are suitable for use in a variety of experimental systems, including cultured cells and transgenic animals. 
Figure 2. Methods currently used to study miRNA expression and function.  
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Websites are dedicated to identification of microRNA gene targets, and experimental valida-
tion of these in silico data: miRBase (http://www.mirbase.org/), Tarbase (di-
ana.cslab.ece.ntua.gr/DianaToolsNew/index.php?r=tarbase/index), MicroRNA.org 
(http://www.microrna.org/microrna/home.do) or miRdb (http://mirdb.org/miRDB). They were 
described above. Unfortunately, as of today, the results given by the various websites are often 
very different from each other and the informations must therefore be subject to careful scruti-
ny. An interesting complement is provided by Patrocles (http://www.patrocles.org/). This 
software attends to the referencing of polymorphisms (Single nucleotide polymorphisms, SNP, 
mostly) and the interactions between target genes and relevant miRNAs in seven vertebrate 
species. Significant progress will certainly come from this sort of research efforts in the next 
few years since it is now increasingly clear that non-coding SNPs provide a potential mecha-
nism for transmission of phenotypes and diseases. Finally, biochemical approaches, using 
affinity purification, are also being developed for direct empirical detection of miRNA associ-
ating with the 3'UTR of mRNA targets [21].  
3. MicroRNAs are implicated in the pathophysiology of vascular smooth 
muscle cells 
VSMCs are not terminally differentiated cells like skeletal and cardiac muscle cells. They have 
a remarkable plasticity which allows them to undergo phenotypic modulation inducing a 
switch from a “synthetic” to a “contractile” phenotype, in response to physiological and patho-
logical environmental cues. On one hand, vascular injury or growth factors like PDGF provoke 
VSMC dedifferentiation which, as a consequence, transdifferentiates the cells into a highly 
migratory and proliferative (“synthetic”) phenotype necessary for vascular repair or angio-
genesis. On another hand, Transforming Growth Factor-β (TGF-β) and its related family 
member Bone Morphogenetic Protein 4 (BMP4) promote differentiation into a less migratory 
and less proliferative phenotype known as the “contractile” phenotype. This VSMC phenotyp-
ic modulation, called transdifferentiation, is characterized by significant changes in cellular 
gene expression pattern. In particular, high expression of VSMC-specific genes, such as 
smooth muscle α-actin (SMαA), calponin1 (CNN), and SM22α (SM22) are associated with the 
contractile phenotype. Transcription of contractile genes is regulated by SRF through a DNA 
sequence motif known as the CArG box (CC(A/T)6GG) which is present in the promoter of 
VSMC-specific genes. A coactivator (and binding partner) of SRF, myocardin, activates VSMC 
expression of key contractile genes ([22-23]. 
The recent emerging role of miRNAs in gene expression regulation via gene silencing 
(through mRNA degradation or translation inhibition) suggests a role for these small nucleic 
acids in VSMC phenotypic regulation. Indeed, numerous publications have documented 
their importance through in vitro and in vivo studies in the cardiac and vascular biology 
fields and their related diseases [24]. This important role of miRNAs in VSMC development, 
differentiation, and related pathologies has been emphasized by two independent teams [25-
26] that independently showed that knock-outing the miRNA processing enzyme Dicer in 
murine VSMCs provokes severe vascular abnormalities, resulting in embryonic lethality. 
Among vascular miRNAs, miR-143 and miR-145 are the most documented to date, and will 
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be explored in greatest detail. They are the most highly expressed miRNAs in smooth mus-
cle cells, and their down-regulation is directly associated with a phenotypic switch from 
contractile, i.e. fully differentiated to synthetic, i.e. proliferative, VSMCs. Other miRNAs 
such as miR-21, miR-221 and miR-222 also have demonstrated roles in VSMC differentia-
tion. Their functions in smooth muscle will also be described. See Figure 3A for a pictorial 
representation of their roles in VSMCs. 
 
Figure 3. (A) Main micro-RNAs involved in the regulation of smooth muscle cell phenotype, including 
transdifferentiation from synthetic to contractile phenotype and (B) main micro-RNAs involved in 
cardiac muscle cell physiopathology.  
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3.1. The miR-143/145 cluster 
The bicistronic unit which encodes miR-143 and miR-145 is critical for maintaining the 
VSMC contractile phenotype. For example, miR-143 and miR-145 are down-regulated in 
synthetic VSMCs [19-20] when VSMC dedifferentiation is induced by PDGF and during 
neointimal formation [27]. On the opposite, TGFβ1 (Transforming Growth Factor 1), a 
strong activator of VSMC differentiation, stimulates both miRNAs expression in a dose- and 
time-dependent manner [27]. The transcription of miR-143/145 is under the control of two 
independent signaling pathways: SRF/myocardin/Nkx2.5 and Jag-1/Notch signaling [28]. 
The expression of miR-143/145 is drastically reduced in several models of vascular disease: 
carotid artery ligation injury in mouse, carotid balloon-injury in rat, and ApoE Knock-out 
mice [27]. In miR-143 or miR-145 KO mice, abnormal vascular tone and reduced contractile 
activity have been detected but VSMCs are functional [29]. Moreover, miR-143/145 levels are 
decreased in aortas from patients with aortic aneurism and lower circulating levels are de-
tected in the serum of patients with coronary artery disease [20-22]. Overexpression of miR-
145 induced lower neointima formation in balloon-injuried arteries [27].  
Dimmeler and colleagues showed recently an example of vesicle-mediated miRNA transfer 
between human vascular endothelial cells and human aortic SMCs [30]. Blood vessels 
exposed to laminar blood flow undergo high shear stress. It is known that under shear stress 
conditions vascular endothelial cells overexpress the transcription factor Krüppel-like factor 
2 (KLF2) which in turn induces up-regulation of miR-143 and miR-145. MiR-143/145 are 
transported in extracellular vesicles such as exosomes and they reduced the expression of 
miR-143 and miR-145 specific targets in co-cultured VSMCs. Additionally, the authors 
showed that extracellular vesicles derived from KLF2-expressing endothelial cells decrease 
atherosclerotic lesion formation in the ApoE KO mice kept on a high fat diet [30]. 
3.2. MiR-21, miR-221, and miR-222 
In contrast to miR-143/145, miR-21, miR-221, and miR-222 are up-regulated in neointimal lesions. 
TGF-β and its related family member BMP4 promote contractile gene expression and VSMC 
differentiation. Interestingly, they induce the transcription of the miR-143/145 cluster and 
promote also an increased expression of miR-21 post-transcriptionally. The critical target of 
miR-21 that is down-regulated in this process is programmed cell death 4 [22]. As a conse-
quence, miR-21 induces VSMCs transdifferentiation to the contractile phenotype in response to 
BMP4 and TGFβ [31]. Additionally, miR-21 promotes VSMC proliferation and reduces apop-
tosis [32]. These miR-21 actions were confirmed in balloon-injured rat carotid arteries [33]. 
Moreover, knock-down of mir-21 using antisense oligonucleotides (antogomiRs) in the rat 
decreases vascular remodeling following balloon injury in carotid arteries [32]. Although an 
increase in differentiation is usually coupled to a decrease in proliferation, this is not necessari-
ly the case in VSMCs. MiR-21 indeed targets a diverse set of genes and mediates differential 
biological outcomes depending on the cellular context [22]. 
Mir-221 and miR-222 genes are clustered on the X chromosome and share a common seed 
sequence. Some reports indicate that they are transcribed from a common promoter [34]. 
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Mir-221 and miR-222 contribute to VSMC dedifferentiation from the differentiated / contrac-
tile to the undifferentiated / synthetic phenotype and thus to increased cellular proliferation. 
Indeed, miR-221 and miR-222 are strongly elevated in vivo in VSMC following balloon inju-
ry of the vessel. Knock-down of mir-221 and miR-222 in the vessel reduced VSMC prolifera-
tion and neointimal lesion formation after angioplasty. Mir-221 and miR-222 are important 
for PDGF-cell mediated proliferation, by repressing tyrosine kinase c-kit, p57Kip2 and the 
cyclin-dependent kinase inhibitor p27Kip1. Interestingly, inhibition of c-kit reduced the ex-
pression of myocardin [32,35]. Overexpression of miR-221 induces an important decrease of 
myocardin expression, even if this miRNA does not target myocardin directly. Instead, it is 
the down regulation of c-Kit that is responsible for the up-regulation of myocardin. MiR-221 
overexpression also increases during VSMC migration but the targets are still unknown. All 
these findings provide an example of the potential of one miRNA to mediate various cellu-
lar outcomes by regulating multiple targets [22,32]. 
4. MicroRNAs are implicated in the pathophysiology of cardiac muscle 
cells 
Cardiovascular pathologies represent the prevalent causes of human morbidity and mortali-
ty in the Western hemisphere. As a consequence, a vast number of research groups consider 
that studying heart molecular and cellular characteristics is a major step in order to develop 
novel diagnostic and therapeutic strategies and to counteract cardiovascular diseases. It is 
now clear that miRNAs are an important part of the complex transcriptional and posttran-
scriptional regulatory circuit essential for the homeostasis of the cardiac tissue. They are 
powerful modulators in virtually all aspects of cardiac biology, from cardiac development to 
cardiomyocyte survival and hypertrophy, which we will now describe in more detail in this 
subchapter. 
In the recent literature, more than a hundred microRNAs have been described as stably 
expressed in the cardiac tissue [36-38]. However, the vast majority (90%) of these miRNAs 
are represented by no more than 18 miRNAs in the mature murine organ. Even more re-
markable is the fact that all these 18 miRNAs show an altered expression in pathological 
conditions, including coronary artery diseases and cardiomyopathies. Interestingly, it has 
been shown that a strong characteristic of these various models of cardiovascular disorders 
is the re-expression of a fetal cardiac miRNA program. This miRNA expression will finally 
trigger the over-expression of several fetal proteins, such as the atrial and brain natriuretic 
factor genes and the fetal isoform of the β-Myosin Heavy Chain gene (βMHC). Exploring 
further how miRNAs regulate gene expression in the heart will thus provide us with unique 
mechanistic insights into cardiac diseases. We will now describe in further details the miR-
NAs which have been the most implicated in the process. See Figure 3B for a pictorial repre-
sentation of their roles in cardiac muscle. 
4.1. Anti-hypertrophic miRNAs 
Muscle miRNAs, such as miR-1 and miR-133, are integrated into myogenic regulatory net-
works: their expression is under the transcriptional and posttranscriptional control of myo-
Current Basic and Pathological Approaches to  
the Function of Muscle Cells and Tissues – From Molecules to Humans 
 
192 
genic factors, and they in turn have widespread control of the muscle gene expression pro-
gram. Recent studies demonstrated that both miR-1 and miR-133 are significantly downreg-
ulated in hypertrophic and failing hearts. They play major roles in the development of car-
diac hypertrophy, and have thus been nicknamed anti-hypertrophic miRNAs. In addition, 
miR-1 and the related miRNA miR-133 arise from a common precursor RNA which is regu-
lated by the transcription factors Serum Response Factor (SRF) and Myocyte Enhancer Fac-
tor 2 (MEF2, [37]), which clearly suggest their importance in an intricate cardiac regulatory 
network. 
The mature miR-1 transcript is the product of two genes, miR-1-1 and miR1-2, and it is now 
proven that its elevation induces arrhythmia in cardiac disease states. Its expression is spe-
cific for both cardiac and skeletal muscle. Overexpression of mature miR-1 in rat exacerbates 
cardiac arrhythmia whereas its knock-down by an antagomiR in the same animal, in the 
infarcted heart relieves arrhythmogenesis [39]. MiR-1 is also overexpressed in individuals 
with coronary artery disease. Part of miR-1 action is mediated by down regulation of con-
nexin 43 and the inward rectifier K channel (Kir2.1, [39]). Another important role of miR-1 is 
to modulate cardiac excitation–contraction coupling by selectively increasing phosphoryla-
tion of the L-type and RyR2 channels via disrupting localization of PP2A activity to these 
channels [40]. Determining plasma levels of miR-1, using qPCR techniques (see subchapters 
II and VI) can be used as a sensitive biomarker for myocardial infarction and its expression 
is strongly down-regulated in hearts from patients afflicted with myocardial infraction 
compared to healthy adult hearts [41]. 
There are three known mir-133 genes: mir-133a-1, mir-133a-2 and mir-133b found on chromo-
somes 18, 20 and 6 respectively. In the human genome, all three genes encode miRNA with 
identical mature sequence [42]. Actually, miR-133a-1 and miR-133a-2 are each expressed bi-
cistronically with miR-1-1 and miR1-2. Knockdown experiments of miR-133 gave at first puz-
zling results: in vitro overexpression of miR-133 or miR-1 inhibited cardiac hypertrophy while 
infusing mice with antagomiRs against the mature miR-133 sequence induced cardiac hyper-
trophy [43]. On the other hand, genetic models with knockout of either mir-133a gene did not 
display significant cardiac pathologies, or actually any phenotype. However, deleting both 
mir-133a genes resulted in a drastic phenotype: ectopic expression of cardiac-specific markers 
genes in VSMCs, embryonic lethality, and aberrant proliferation of cardiac muscle cells [37]. 
The phenotypic difference between mice treated by antagomiRs at the adult stage, and genetic 
models which have been deprived from miRNAs from conception clearly shows the limits of 
both models. The sum of these studies however clearly emphasizes the role of the miR-133 
mature sequence in cardiac muscle biology. On a mechanistic side, Horie et al. [44] have 
shown a direct role of miR-133 in cardiomyocyte glucose transport: overexpression of the 
miRNA decreased levels of the glucose transporter GLUT4 and reduced insulin-induced glu-
cose uptake. Additionally, this increase of miR-133 reduced Krüppel-like transcription factor 
15 (KLF15) expression, which induces GLUT4 expression.  
4.2. Pro-hypertrophic miRNAs 
The role of mir-21 in cardiac modeling and pathophysiology is clearly controversed. MiR-21 
inhibition by antagomir strategies was first reported as causing an alleviation of murine 
 
Implication of MicroRNAs in the Pathophysiology of Cardiac and Vascular Smooth Muscle Cells 
 
193 
cardiac hypertrophy [38,45]. A divergence arose when the first team attributed this pro-
hypertrophic effect to an effect on cardiomyocytes [38] whereas the second team claimed the 
primary site of miR-21 action was actually cardiac fibroblasts [45]. In contrast to both team 
results, Cheng et al. [46] reported that miR-21 was indeed increased by fourfold in 
hypertrophic mouse hearts, but that modulating miR-21 via antisense depletion had a 
significant negative effect on cardiomyocyte hypertrophy. Finally, Patrick et al. [47] found 
that a genetic deletion of the mir-21 gene results in mice with a normal phenotype that did 
not respond differently to normal littermates when exposed to cardiac stress conditions. 
Also, in the same study, LNA-modified antagomiRs specific for miR-21 did not block a 
remodeling response of the murine heart to stress conditions. The authors concluded that, 
although miR-21 is highly up-regulated during cardiac remodeling, it is not essential for 
cardiac hypertrophy, a disease state associated with fibrosis in response to heart injury. 
Nonetheless, miR-21 is a miRNA of interest in the cardiac field, at least as an innovative 
biomarker, since it is almost undetectable in the healthy heart, but is strongly over-
expressed in cardiac pathologies. 
The human miR-29 family of microRNAs is encoded by two gene clusters. As a conse-
quence, three matures members exist: miR-29a, miR-29b, and miR-29c. In this instance, the 
miR-29 family has been shown to be expressed in both cardiac fibroblasts and cardiomyo-
cytes [48]. In these cell types, sixteen of their targets are extracellular matrix genes. This 
clearly shows a striking example of a single microRNA mature sequence which is capable to 
target a large group of functionally related genes. As a consequence, miR-29 expression 
induces strong antifibrotic effects in heart and other tissues. MiR-29s have also been shown 
to be pro-apoptotic and involved in cell differentiation. Acute myocardial infarction due to 
coronary artery occlusion also results in a decrease of the expression of the miR-29 family in 
the region of the fibrotic scar [48]. Using up- and down-regulation of miR-29, the same au-
thors showed that this miRNA regulates the expression of collagens, and as a result the 
fibrotic response. Finally, the miR-29 family has also been shown to down-regulate elas-
tin and other extracellular matrix (ECM) genes implicated in elastogenesis [49]. Jones et al. 
[50] have examined miRNA expression using qPCR in aortic tissue collected from patients 
with ascending thoracic aortic aneurysm and shown that miR-29a expression is correlated 
with cardiac tissue proteolytic degradation and aortic size. These last results show the inter-
est of determining specific miRNA levels in human diagnostic. 
Another miRNA of interest in the cardiac field of investigation is miR-208a, which is ex-
pressed strictly in the heart. Mir-208a overexpression in transgenic mice induces hyper-
trophic growth of the cardiac muscle and induces arrhythmias. This hypertrophic growth is 
concomitant with fibrosis and a decrease of contractility, which results from down-
regulation of the faster isoform, α-myosin heavy chain (α-MHC) and up-regulation of the 
fetal specific, slower isoform, β-MHC [51-52]. Thus, cardiac-specific overexpression of miR-
208a induces cardiac remodeling and regulates the expression of hypertrophic proteins, 
including β-MHC. Conversely, the same authors showed that genetic deletion of miR-208a 
in mouse induces a decrease of β-MHC. Additionally, miR-208 targets other proteins, such 
as thyroid hormone-associated protein 1 and myostatin 2, which are both inhibitors of mus-
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cle growth and hypertrophy, with for final consequence hypertrophic cardiac growth. MiR-
208a is also strongly up-regulated in the diseased human heart as detected in biopsies from 
patients afflicted with myocardial infarction [41]. Also, miR-208a is not detected in plasma 
from healthy patients, but is raised to a detectable level as soon as 1 h after coronary artery 
occlusion [53]. This result is important, since it clearly shows that, at least for this miRNA, 
plasma levels reflect tissue amounts, and thus that miRNA are strong candidates as non-
invasive biomarkers (see subchapter VI for more information on this topic). 
5. The miRNA regulators: Who watches the watchmen? 
Expressional patterns of miRNAs vary according to organs and their developmental stages. 
Indeed, several transcriptional and post-transcriptional processes control the levels of ma-
ture miRNAs. The study of these regulatory mechanisms is still in its very early steps. We 
will review here what is known, starting with other non-coding RNAs which are as long as 
miRNAs are short, we will proceed with transcription factors, and finally explore how cells 
are able to communicate with each other, using microRNAs. 
In the last few years, it has been shown that long non-coding RNAs act as miRNA sponges 
and/or competing endogenous RNAs, are able to regulate miRNA function by binding com-
plementarily with them, thus competing with their dedicated mRNAs targets, and thereby 
to impose an additional level of post-transcriptional regulation. Little is known about the 
mechanisms of action of these exciting new regulatory RNAs in muscle cells. A ground-
breaking result came from Cesana et al [54]: they have identified a long non coding RNA, 
called linc-MD1, in the skeletal muscle. linc-MD1 is stably expressed in mouse and human 
myoblasts, and controls the myogenesis program by binding, and thus “sponging” two 
instrumental miRNAs, miR-133 and miR-135, which in turn regulate transcription factors 
that activate muscle-specific gene expression. By “inhibiting the inhibitors”, linc-MD1 accel-
erates myogenesis. Interestingly, this RNA’s expression is strongly reduced in Duchenne 
muscular dystrophy, a genetic disorder which is characterized by a drastic reduction of 
myoblasts. No equivalent of linc-MD1 has yet been described in smooth muscle biogenesis 
or in cardiogenesis but one can strongly guess that they will be identified in the forseeable 
future. 
Several transcription factors have been characterized as miRNA regulators in smooth, cardi-
ac and skeletal muscle cells, thus revealing novel mechanisms underlying VSMC differentia-
tion. Myocardin is the best characterized in VSMCs and cardiac cells [55]. Myocardin, with 
its co-activator Serum Response Factor (SRF), is a cardiac- and muscle specific trans-acting 
protein, and a master regulator of the smooth muscle phenotype. It has been shown that this 
transcription factor regulates several miRNAs in VSMCs. It induces miR-1 expression, 
which in turn inhibits VSMC proliferation, and increases their differentiation, by targeting 
Pim-1, a serine/threonine kinase [56]. Similarly, myocardin represses versican, a chondroitin 
sulfate proteoglycan of the extra-cellular matrix that is produced by synthetic VSMCs and 
promotes VSMC migration and proliferation, by inducing the expression of miR-143, a miR 
instrumental in VSMC differentiation [57]. SRF has been shown to regulate the expression of 
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several mIRs, including miR-1, miR-133a and miR-21 [58]. Interestingly, myocardin co-
activator SRF regulates microRNA biogenesis, specifically the transcription of pri-
microRNA, thereby affecting the mature microRNA level, by binding to the proximal pro-
moter region of miR genes. Transforming Growth Factor-β1 (TGFβ1), another known stimu-
lus capable of inducing VSMC differentiation, has also been shown to induce both miR-143 
and miR-145 in human coronary artery SMCs [59]. We have already discussed the im-
portance of transcription factors SRF and MEF4 in the regulation of miR-1 and miR-133 (see 
subchapter 5). Finally, although skeletal muscle is outside of the topic of this chapter, it is 
interesting to note that another important muscle-specific transcription factor, MyoD, im-
pacts miR-1 and miR-206 expressions, with strong consequences on myoblast apoptosis 
levels [60]. Although it has not been shown yet, one can speculate that similar systems exist 
in smooth muscle and cardiac muscle cells. 
Decay mechanisms affecting miRNAs in order to regulate their expression are not well un-
derstood. However, new notions have recently been put to the forefront: it seems that 
changes in cellular density and cell adhesion mechanisms affect rapidly miRNAs expression 
[61]. When cells are grown at low density or after cell splitting, some miRNAs are rapidly 
degraded while others remain unaffected. This rapid, and yet unexplained, degradation of 
persistent regulatory molecules such as miRNAs may facilitate cellular plasticity and re-
modeling in response to various stresses. 
Wang et al. [62] have recently shown that several human cell lines from various origins 
(glioblastoma, hepatocytes, lung bronchial epithelium, pulmonary fibroblasts, alveolar basal 
epithelial cells) actively release miRNAs in a short time period of time (approx. 1 h) after 
serum deprivation. Thus, one can hypothesize that, at least some, exported miRNAs are 
used for cell-to-cell communication. More studies will of course be needed to determine 
exactly how miRNAs are specifically targeted to relevant target cells, and what information 
is transduced. It will also be important to determine why evolution has selected several 
different means of transportation for miRNAs: protein complexes, exosomes, Microvesicles, 
High Density Lipoprotein (HDL) or apoptotic bodies (Figure 4). For example, miRNA com-
plexed with proteins, could be targeted to specific cell surface receptors, and miRNAs inside 
vesicles to others targets. All these recent results ask important questions about cell-to-cell 
communication mediated by miRNAs, and raise the possibility that a yet undiscovered 
biological information transduction system exists, and could be important to explain many 
biological processes including development, differentiation, and stress response. In cardio-
vascular diseases, for example, the general decrease in circulating miRNAs detected in pa-
tients with CAD might be caused by a disregulation of this miRNA trafficking system in 
atherosclerotic lesions or in the infarcted myocardium.  
6. MiRNAs: New biomarkers in vascular and cardiac diseases 
Being instrumental players in the fine-tuning of gene regulation networks, microRNAs have 
significant diagnostic and prognostic value, as biomarkers of disease etiology and 
progression. Until recently, however, miRNA quantitation and usefulness as a biomarker 
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was dependent on the availability of the pathological tissue. This was not a major setback 
for the diagnosis of cancer, where biopsies were readily available in most cases, but proved 
to be serious concern when dealing with heart or vascular pathologies. Very recently, these 
concerns were alleviated when several teams showed that miRNAs can be detected and 
precisely measured in human blood (eg [63,64]). These papers, showing a stable presence of 
miRNA in human plasma, came as a surprise. Indeed, any researcher having experience 
with RNA work considers ribonucleic acids as fragile and unable to survive in a liquid like 
serum which contains a wealth of specific and non-specific degrading enzymes.  
 
Figure 4. The various mechanisms of miRNA release from cells in the peripheral blood circulation and 
their uptake in recipient cells. Ago2 Argonaute 2; HDL High density Lipoprotein. 
Stephanie Dimmeler’s pioneer studies show that miRNA can be detected in the serum of 
patients with coronary artery diseases (CAD) and that their levels are altered in patient’s 
serum when compared to healthy counterparts [65] [65-66]. MiRNAs are thus prime 
candidates as novel non-invasive biomarkers in cardiovascular diseases, which can be 
measured in routine clinical diagnosis. The main question here is which endogenous 
referent genes to use as this is instrumental in qPCR. In cardiovascular disease studies, 
various endogenous circulating miRNAs (eg miR-17-5p, miR-454, U6 or RNU6b) have been 
used for normalization of circulating miRNAs, but the use of spiked-in miRNAs, i.e. adding 
a known amount of exogenous non-human miRNA, (eg synthetic Caenhorabditis elegans miR-
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39) is now increasingly common as the experimenter knows clearly the amount of the 
referent miRNA, and no further experimental bias is added [66]. 
An important question is the exact localization of miRNAs in the bloodstream. They exist in a 
highly stable, extracellular form and are remarkably persistent in the RNase-rich environment 
of blood. The first model postulates that circulating miRNAs are protected by encapsulation in 
membrane-bound vesicles such as exosomes, phagosomes, apoptotic bodies…[65-66] Arroyo 
et al. [67] have however recently challenged this view: they used a combination of differential 
centrifugation and size-exclusion chromatography and showed that circulating miRNAs 
cofractionate mostly with protein complexes rather than with vesicles, in human plasma and 
serum. Even more surprising was the fact that the main miRNA binding partner was Ago2, 
the key effector protein of miRNA-mediated silencing, which is considered as a cytosolic pro-
tein. Ago2 seems to be one of the factors protecting circulating miRNAs from plasma RNases, 
since purified miRNAs, devoid of protein partners, were sensitive to RNase treatment. Figure 
4 summarizes the different hypotheses that have been put forward to explain how miRNAs 
can be secreted and exported in human blood. 
Goren et al. [68] have very recently published that four miRNAs, miR-22, miR-92b, miR-320a 
and miR-423-5p were significantly increased in the serum of patients with heart failure. By 
relying on a signature derived from the expression of these miRNAs, the authors were able 
to discriminate between systolic heart failure patients and healthy controls with a sensitivity 
and specificity of 90%. Moreover, there was a significant correlation with important clinical 
prognostic parameters such as an elevated serum natriuretic peptide and a wide QRS. Other 
recent papers have highlighted the interest of determining their levels in serum and other 
body fluids, including urine, feces and saliva [69-70]. This forebodes well for the increasing 
usefulness of specific miRNA expression as non-invasive biomarkers. 
7. Potential of miRNAs as innovative drug targets 
In the last decade, the increasing interest in small RNAs has triggered the arrival of innovative 
drug targets on the pharmaceutical market. Among these small RNAs, miRNAs provide per-
haps the most promising new opportunities for developing new compounds, especially with 
the recent advances in anti-miRNA chemistry. On one hand, therapeutic nucleic acids can be 
administered using lentivirus-mediated antagomir expression, which induces a stable knock-
down phenotype for a specific miRNA [71-72]. On the other hand, the vast majority of anti-
miRs used in trials are in fact altered locked nucleic acids (LNA), also known as inaccessible 
RNA (reviewed in [73]). The canonic nucleic acid ribose sugar backbone is modified with an 
extra bridge connecting the 2' oxygen and 4' carbon [74]. This conformation enhances base 
stacking and backbone pre-organization, which will significantly enhance the hybridization 
properties for the compounds. These poly-anionic molecules tend to distribute broadly but 
also to accumulate in liver, kidney and phagocytes. They are highly hydrophilic, with a mo-
lecular weight ranging from 2 to 6 kD. For the moment, routes of administration used are 
essentially intravenous and subcutaneous injections [75-76]. One has however got to keep in 
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mind that developing innovative drugs is risky, represents a tremendous cost in resources, 
time, etc., and should not be undertaken lightly.  
A first clinical trial, in this post-genome era, is under way in human patients affected by 
viral hepatitis C. Phase IIa results of this promising trial, focusing on the liver-specific miR-
122 [77], aims to develop the related drug called Miravirsen, developed by Santaris Pharma 
A/S as a LNA antagomir, and thus to antagonize miR-122, which is instrumental for Hepati-
tis C virus C (HCV) infection. Langford et al. [78] had already shown in primates that a 
LNA-specific for miR-122 was able to suppress HCV viremia, with no evidence of viral 
resistance or side effects in the treated animals. These promising results are confirmed in 
humans and show that using an antagomir approach induces a decrease of the patient’s 
viral load, and that this revolutionary treatment is less toxic and more effective than current 
medicine (http://www.santaris.com/news/2011/11/05/santaris-pharma-phase-2a-data-
miravirsen-shows-dose-dependent-prolonged-viral-reduct), perhaps due to the specificity 
brought by RNA strand complementarity.  
Concerning cardiovascular diseases, we will now focus on the expanding interest of miR-
NAs in cardiovascular molecular medicine, and the various studies that have been under-
taken, on animal models, for the time being. 
The important role of the miR-29 family of microRNAs has already been evoked in this 
chapter (see subchapter V). A promising study dealt with their effects in two murine models 
of abdominal aortic aneurysm (AAA) (porcine pancreatic elastase [PPE] infusion model in 
C57BL/6 mice and the AngII infusion model in ApoE-/- mice). Antagomirs against miR-29b 
was administered in vivo under the form of LNA. This resulted in an increase of collagen 
expression [79], which resulted in an early fibrotic response in the aortic wall and an actual 
reduction of AAA progression in both models. Conversely, overexpression of miR-29b using 
lentiviral vectors resulted in an aggravation of AAA, and a premature rupture of the aortic 
wall. This miRNA is thus a promising target for creating an innovative treatment for AAA. 
Matkovich et al. [80] have shown that over-expression of miR-133a in the heart of transgenic 
mice prevented TAC-associated miR-133a downregulation and improved myocardial fibro-
sis and diastolic function. In another, more exotic, model, Yin et al. [81] have shown that 
miR-133 restricts injury-induced cardiomyocyte proliferation. 
Very recently, miR-33, although not specific for cardiac or vascular tissues, has gained a 
lot of attention in atherosclerosis treatment [82]. Both miR-33a and miR-33b target the 
adenosine triphosphate-binding cassette transporter A1 (ABCA1), an important regulator 
of high-density lipoprotein (HDL) synthesis and reverse cholesterol transport in a murine 
model. Inhibiting miR-33 using two different methods (overexpression of dedicated lenti-
viral particles or injection of LNA antagomiRs) led to an up-regulation of ABCA1 and 
importantly to an increase of cholesterol influx and concomitant increase in the levels of 
HDL, and thus of atheroprotective effects. These authors show thus clearly that increas-
ing HDL levels in Mouse via miR-33-specific antagomiRs promotes reverse cholesterol 
transport and suggest that it may be a promising strategy to induce atherosclero-
sis regression. Several months later, the same team published similar results in primates, 
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more precisely African green monkeys [83]. In addition to the beneficial effects already 
detected in Mouse, the authors showed a strong decrease of plasma levels of very-low-
density lipoprotein (VLDL)-associated triglycerides. This difference can tentatively be 
attributed to the presence of miR-33b in the SREBF1 gene of medium and large mammals 
and its absence in rodents. Pharmacological use of antagomiRs specific for miR-33a and 
miR-33b is thus able to markedly raise plasma HDL and lower VLDL triglyceride levels 
and therefore a promising therapeutic strategy to treat dyslipidaemias, and their induced 
cardiac consequences in human patients. 
8. In conclusion: MicroRNAs, a bright future? 
In the last decade, many advances have been made to decipher miRNA roles in cardiovascu-
lar development and pathogenesis. New methods have been developed in order to use them 
as innovative biomarkers in diagnostics, and as groundbreaking drugs in pharmacological 
treatments. A first, promising, clinical trial in humans is in progress right now. However, 
many questions remain still to be answered. Each miRNA targets up to one hundred mRNA 
targets, which poses significant challenges to the identification, and specific targeting, of the 
mRNAs that are relevant to a particular pathological process. On the other hand, this prob-
lem could also become a solution, since it is now clear that a particular family of miRNAs is 
associated with the same disease type [84]. So it could prove more efficient to target a prede-
fined network of related miRNAs rather than a single one [85]. 
With the current pace of evolution in understanding the basic ways of miRNA action in 
cardiovascular development and disease, one can safely trust that these small molecules will 
still amaze us with more revelations in the near and not so near future.  
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